Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Labetuzumab Govitecan||Phase Ib/II||Actionable||In a Phase I/II trial, treatment with Labetuzumab govitecan demonstrated safety and resulted in stable disease in 49% (42/86), a clinical benefit rate of 29% (25/86; 1 partial response and stable disease for at least 6 months in 24), a median progression-free survival of 3.6 months, and a median overall survival of 6.9 months in patients with previously treated recurrent or refractory colorectal cancer (PMID: 28817371; NCT01605318).||detail... 28817371|
|PubMed Id||Reference Title||Details|
|Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results||Full reference...|
|(28817371)||Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.||Full reference...|